Education
About Us
Working with TipRanks
Follow Us
Aptose Biosciences (APTOF)
OTHER OTC:APTOF
APTOF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.64 - $14.29
Previous CloseN/A
VolumeN/A
Average Volume (3M)4.80K
Market Cap
$3.04M
Enterprise Value$16.69M
Total Cash (Recent Filing)$553.00K
Total Debt (Recent Filing)$11.38M
Price to Earnings (P/E)―
Beta-0.16
Next Earnings
Nov 06, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.76
Shares Outstanding2,552,429
10 Day Avg. Volume3,303
30 Day Avg. Volume4,801
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap5.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.83
Forecast
1Y Price Target
$6.00Price Target Upside380.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentTuspetinib is a highly differentiated kinase inhibitor with favorable safety and broad activity across difficult-to-treat AML subpopulations, including those with TP53, RAS, and FLT3 mutations.
Clinical Study ResultsTUSCANY exhibits initial signs of promise in newly diagnosed AML, with initial safety and efficacy data showing favorable outcomes.
Financial PositionThe company ended the year with $6.7 million in cash, which management believes should provide runway for ongoing operations through April 2025.
Bears Say
Funding NeedsAptose is working with its partner Hanmi Pharmaceutical to negotiate a new tuspetinib co-development collaboration agreement to provide necessary additional funding and accelerate clinical development of tuspetinib.
Aptose Biosciences News
APTOF FAQ
What was Aptose Biosciences’s price range in the past 12 months?
Aptose Biosciences lowest stock price was $0.64 and its highest was $14.29 in the past 12 months.
What is Aptose Biosciences’s market cap?
Aptose Biosciences’s market cap is $3.04M.
When is Aptose Biosciences’s upcoming earnings report date?
Aptose Biosciences’s upcoming earnings report date is Nov 06, 2025 which is in 74 days.
How were Aptose Biosciences’s earnings last quarter?
Aptose Biosciences released its earnings results on Aug 13, 2025. The company reported -$2.76 earnings per share for the quarter, missing the consensus estimate of -$2.74 by -$0.02.
Is Aptose Biosciences overvalued?
According to Wall Street analysts Aptose Biosciences’s price is currently Undervalued.
Does Aptose Biosciences pay dividends?
Aptose Biosciences does not currently pay dividends.
What is Aptose Biosciences’s EPS estimate?
Aptose Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aptose Biosciences have?
Aptose Biosciences has 2,552,429 shares outstanding.
What happened to Aptose Biosciences’s price movement after its last earnings report?
Aptose Biosciences reported an EPS of -$2.76 in its last earnings report, missing expectations of -$2.74. Following the earnings report the stock price went up 5.645%.
Which hedge fund is a major shareholder of Aptose Biosciences?
Currently, no hedge funds are holding shares in APTOF
Company Description
Aptose Biosciences
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Technical Analysis
XORTX Therapeutics Inc
―
Core One Labs
―
―
BioVaxys Technology
―
Rakovina Therapeutics Inc
―
Ownership Overview
24.03% Insiders
0.94% Other Institutional Investors
75.03% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---